Last reviewed · How we verify
Merck Glucophage® high dose
At a glance
| Generic name | Merck Glucophage® high dose |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- White blood cells in urine
- Hyperglycaemia
- Headache
Key clinical trials
- Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions. (PHASE1)
- Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions. (PHASE1)
- A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together (PHASE1)
- Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) (PHASE3)
- Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Merck Glucophage® high dose CI brief — competitive landscape report
- Merck Glucophage® high dose updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI